Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine

Trade name: Kinrix

Vaccineapproved

Approved

Jun 24, 2008

The DPT vaccine or DTP vaccine is a class of combination vaccines to protect against three infectious diseases in humans: diphtheria, pertussis, and tetanus (lockjaw). The vaccine components include diphtheria and tetanus toxoids, and either killed whole cells of the bacterium that causes pertussis or pertussis antigens. The term toxoid refers to vaccines which use an inactivated toxin produced by the pathogen which they are targeted against to generate an immune response. In this way, the toxoid vaccine generates an immune response which is targeted against the toxin which is produced by the pathogen and causes disease, rather than a vaccine which is targeted against the pathogen itself. The whole cells or antigens will be depicted as either "DTwP" or "DTaP", where the lower-case "w" indicates whole-cell inactivated pertussis and the lower-case "a" stands for "acellular". In comparison to alternative vaccine types, such as live attenuated vaccines, the DTP vaccine does not contain any live pathogen, but rather uses inactivated toxoid to generate an immune response; therefore, there is not a risk of use in populations that are immune compromised since there is not any known risk of causing the disease itself. As a result, the DTP vaccine is considered a safe vaccine to use in anyone and it generates a much more targeted immune response specific for the pathogen of interest. — Wikipedia

Clinical trial activity

108 trials · 47 clinical orgs · 0 marketing orgs

Phase 1
12
Phase 2
79
Phase 3
65
Phase 4
14

Earliest trial started Sep 1, 2000 (NCT00879827)

Timeline

2000s

  1. Jan 1, 2000

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2000

    Earliest Phase 3 Sponsor(trial)

  3. Jun 24, 2008

    Earliest FDA Approval

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedJun 24, 2008

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • daptacel
  • dpt-ipv
  • dtap-ipv mkc vaccine
  • gsk217744
  • gsk2202083a
  • infanrix
  • infanrix ipv
  • infanrix-ipv/hib
  • infanrix penta
  • kinrix
  • repevax
  • revaxis
  • tdap-ipv vaccine
  • tdcp-ipv vaccine
  • tetravac tm
  • tetravax-dv
  • tetravax-dv-tv003
  • tetravax-dv tv005
  • tetravax-dv-tv005
  • tetraxim

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07203755Phase 1Oct 22, 2025Government of China, Tianjin Cansino Biotechnology Inc
NCT07160244Phase 3Aug 25, 2025Pfizer
NCT07112144Phase 3Jun 13, 2025Changchun BCHT Biotechnology Co., Government of China
NCT06708286Phase 2/Phase 3 (Phase 3)Dec 18, 2024Tianjin Cansino Biotechnology Inc
NCT06618196Phase 2Oct 2, 2024LG
NCT06805487Phase 1Sep 24, 2024Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID)
NCT06184542Phase 1Dec 23, 2023Chinese Academy of Medical Sciences, Government of China
NCT06344065Phase 3Dec 21, 2023Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
NCT05951725Phase 3Aug 11, 2023Tianjin Cansino Biotechnology Inc
NCT05155579Phase 1Feb 28, 2022Malaria Research and Training Center, Bamako, Mali, University of Oxford
NCT05193734Phase 2/Phase 3 (Phase 3)Feb 7, 2022University of Geneva, University of Genoa
NCT05116241Phase 2Nov 30, 2021ILiAD Biotechnologies
NCT05091619Phase 3Oct 22, 2021Beijing Tiantan Bio Co., Ltd, China National Biotec Group Co., Ltd, Government of China
NCT04490018Phase 3Mar 16, 2021Sanofi, Sanofi-Aventis
NCT07213089Phase 2/Phase 3 (Phase 3)Jul 13, 2020BioNet-Asia Co., Ltd., Mahidol University, National Science and Technology Development Agency, Thailand
NCT04429295Phase 3Jun 29, 2020Sanofi-Aventis
NCT04300192Phase 4Mar 9, 2020Sanofi, Sanofi-Aventis
NCT03891758Phase 3Apr 1, 2019Mitsubishi Tanabe, Osaka University
NCT03632720Phase 3Oct 31, 2018Sanofi-Aventis
NCT04133987Phase 2Oct 15, 2018Government of Taiwan, National Taiwan University
Showing 20 of 108 trials
Page 1 / 6

Organizations

Research & Development (47)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit484832000
SanofiFor profit131222001
Sanofi-AventisFor profit12622001
Johns Hopkins UniversityAcademic/Hospital8012010
National Institute of Allergy and Infectious Diseases (NIAID)Government8812010
MerckFor profit5522006
Government of ChinaGovernment4022021
Mitsubishi TanabeFor profit3322014
Tianjin Cansino Biotechnology IncFor profit3322023
Osaka UniversityAcademic/Hospital2012016
PfizerFor profit2222011
Public Health EnglandGovernment2212013
University of OxfordAcademic/Hospital2222014
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.For profit1112023
Banco Nacional de Desenvolvimento Economico e SocialGovernment1012013
Beijing Tiantan Bio Co., LtdFor profit1012021
BioNet-Asia Co., Ltd.For profit1112020
Butantan FoundationAcademic/Hospital1012013
Butantan InstituteAcademic/Hospital1112013
Centre Hospitalier le MansAcademic/Hospital1112018
47 organizations
Page 1 / 3